Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer

Similar documents
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer

Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122

Pre-operative assessment of patients for cytoreduction and HIPEC

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

SURGICAL MANAGEMENT OF EPITHELIAL OVARIAN CANCER PARSGO, MARRAKECH 2018

Ovarian cancer: clinical practice the Arabic perspective

North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary

U T C H. No disclosure

Epithelial Ovarian Cancer

LAPAROSCOPY and OVARIAN CANCER

From Research to Practice: What s New in Gynecologic Cancers?

Prof. Dr. Aydın ÖZSARAN

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database

Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES

Clinical Audit Data: 01 October 2015 to 30 September West of Scotland Cancer Network. Gynaecological Cancer Managed Clinical Network

PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC

Enterprise Interest None

is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the

Ovarian cancer. Quick reference guide. Issue date: April The recognition and initial management of ovarian cancer

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Gynaecological Oncology Cases

Index. B Bilateral salpingo-oophorectomy (BSO), 69

Ovarian Cancer Quality Performance Indicators (QPI) Comparative Report

Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital

Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012

Laparoscopia & carcinosi ovarica. Anna Fagotti Gynecologic Oncology

Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review: Version No. 1.1 Supercedes 1.0 Links to other policies

Research Article Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer

THORACIC MALIGNANCIES

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

10/24/14. Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches. Disclosure. Learning Objectives

LA CHIRURGIA PRIMARIA

Endometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines

Management of Ovarian Cancer

Case Report Laparoscopic Diagnosis of Adenocarcinoma of the Appendix Mimicking Serous Papillary Adenocarcinoma of the Peritoneum


North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer

Ovarian Cancer Quality Performance Indicators

Ovarian Cancer Audit Comparative Annual Report 01/01/ /12/2009

How to deal with patients with isolated peritoneal metastases

TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

Maria João Cardoso, MD, PhD

7. Cytoreductive surgery in endometrial cancer and uterine sarcomas

Cytoreductive Surgery for Advanced Epithelial Tumors of the Ovary: Technical Considerations and Outcome

Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer

Eligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment

NAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Imaging in gastric cancer

FDG-PET/CT in Gynaecologic Cancers

Colorectal peritoneal metastases and IMPACT

Chapter 8 Adenocarcinoma

Co-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Audit Report Report of the 2012 Clinical Audit Data

Anshuma Bansal 1 Bhavana Rai

Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases

Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin

Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

Current state of upfront treatment for newly diagnosed advanced ovarian cancer

CNGOF Guidelines for the Management of Endometriosis

HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies

Extraovarian Primary Peritoneal Carcinomatosis: A Case Report

How to Define, Evaluate, and Identify Surgical Quality. Viewpoint of the ESGO Quality Assurance Committee

Interactive Staging Bee

OVARIAN CANCER 2011 COMPARATIVE AUDIT REPORT

Endometrial Cancer. Incidence. Types 3/25/2019

Case Report Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer

Been Diagnosed with Ovarian Cancer, Now What?

Prospective study evaluating a strategy of surgery alone and surveillance in FIGO stage I malignant ovarian germ cell tumor (KGOG 3033)

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus

Ovarian Tumors. Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center

Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

Para-aortic laparoscopic lymph-node dissection for advanced cervical cancers

OVARIAN CANCER ANNUAL REPORT

SURGERY OF RECURRENCIES

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Diagnosi, inquadramento clinico e chirurgia

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer

Squamous cell carcinoma arising in a dermoid cyst of the ovary: a case series

Endometrial cancer. Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology.

Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei

Gynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer

CT PET SCANNING for GIT Malignancies A clinician s perspective

11/21/13 CEA: 1.7 WNL

Appendix 4 Urology Care Pathways

LCA Gynaecological Cancer Clinical Guidelines

Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now

INTERACTIVE SESSION 2

Practice of Medicine-1 Ovarian Cancer Clinical Correlation

Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study

Transcription:

Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru

Suitable candidates for neo-adjuvant chemotherapy Primary surgery is the standard treatment for stages I-II The potential indications of neo-adjuvant chemotherapy are confined to stages III-IV

Principles of surgery Whether performed primary or as an interval debulking procedure, cytoreductive surgery must be complete (leaving no gross macroscopic residual disease), Suboptimal cytoreductive surgery must be avoided Level 1 Grade A

Pre-treatment workup A pre-treatment assessment of resectability is recommended (1) Clinical evaluation taking into account the general condition (ECOG score or Karnofsky index) and nutritional status (weight, albumin and pre-albumin tests) of the patient Anaesthesiology workup (ASA score) Laboratory test workup: CA 125, CA 19-9 if mucinous tumor Expert opinion

Pre-treatment workup A pre-treatment assessment of resectability is recommended (2) Radiological workup: Chest-abdominal-pelvic CT scan MRI is not recommended as part of the standard workup Expert opinion PET scan is not recommended as part of the standard workup for stages III but is optional for some cases of stage IV disease Laparoscopy is the best way of assessing initial resectability Findings complete the information provided by imaging and laboratory tests Also provides the histological diagnosis (biopsy) indispensable for therapeutic decision-making Level 2 Grade A

Evaluation of Peritoneal Extent by Surgery (quality criterion) Use of a carcinomatosis extent evaluation score is recommended Laparoscopic evaluation: Fagotti score Median laparotomy with a view to complete cytoreduction: Sugarbaker's Peritoneal Cancer Index (PCI) Level 2 Grade A

Extent and Resectability by Faggoti laparoscopic score Fagotti laparoscopic score (2008) Omental cake Peritoneal carcinomatosis Diaphragmatic carcinomatosis Mesenteric retraction Stomach infiltration Liver metastases Each parameter was attributed a score of 0 to 2 Cytoreduction is incomplete in 100% of patients with a score 8

Sugarbaker's extension score at laparotomy Sugarbaker's Peritoneal Cancer Index (PCI) Milan Consensus Conference 2006 PCI from 0 to 39

Cytoreductive surgery Surgery must include at least: Complete hysterectomy with oophorectomy Infragastric total omentectomy Appendicectomy Dissection of pelvic and lumboaortic lymph nodes (in the case of otherwise complete cytoreductive surgery) Expert opinion

CCR Residual Disease Score CCR: completeness of cancer resection score Size of largest node at the end of surgery

Operative report after laparotomy Useful history (e.g. hysterectomy for fibroma) Description of treatment strategy (initial surgery or debulking surgery after X courses) Sugarbaker's peritoneal carcinomatosis dissemination PCI score FIGO stage The operative report must include (surgery quality criterion) Description of surgical procedures performed CCR score describing the size of the residual tumour at the end of the procedure Expert opinion

Indication for neoadjuvant chemotherapy Use of neoadjuvant chemotherapy must be discussed in the Pretreatment Multidisciplinary Staff Meeting before treatment is started Neoadjuvant chemotherapy can be offered for stage III malignancy (stage IV disease will be discussed separately) if: There are medical and/or anaesthetic contraindications for primary surgery Carcinomatosis extent does not allow a primary complete cytoreduction, this has to be assessed by a trained surgical team Level 1 Grade A

Neoadjuvant chemotherapy Chemotherapy is a combination of carboplatin and paclitaxel Level 1 Grade A Anti-angiogenic agents (bevacizumab) must not be given in combination with neoadjuvant chemotherapy before surgery Expert opinion

Number of courses The teams must cooperate closely to ensure the consistency between the different treatments Three courses must be given before surgery is proposed. Level 2 Grade B If interval debulking surgery is performed after more than 3 neoadjuvant chemotherapy courses, the procedure must be followed by at least 2 courses of adjuvant chemotherapy Expert opinion

Stage IV A PET scan may usefully supplement the staging procedure In the event of pleural uptake, a pleuroscopy may be appropriate before abdominopelvic surgery In most cases, initial management consists of neoadjuvant chemotherapy Expert opinion Surgery must aim to be as complete as possible. Systematic review of the indication on a case by case basis in the pre-treatment MSM either immediately by an experienced surgical team to achieve complete cytoreduction in suitable candidates for supra-radical surgery or after a response to neoadjuvant chemotherapy has been obtained